The development of agonistic antibodies involves several key steps, starting with the identification of a target receptor whose activation could yield therapeutic benefits. Researchers then generate antibodies that can bind to and activate this receptor. This process often involves screening large libraries of antibody candidates to identify those with the desired agonistic properties. Subsequent optimization steps aim to enhance the antibody's affinity, specificity, and stability. Techniques such as phage display and hybridoma technology are commonly employed in this process.
